---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-002104"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2022-01-20T23:59:59+00:00"
generated_at: "2026-06-27T17:00:45.096762+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Brooklyn ImmunoTherapeutics appoints Heather B. Redman and Erin S. Enright to board

## Summary
- Board expanded from 5 to 6; Redman and Enright appointed Jan 14, 2022.
- Redman is Managing Partner at Flying Fish Partners; Enright is Managing Member at Prettybrook Partners.
- Each received option for 67,000 shares of common stock under 2020 Plan, vesting over 3 years.
- Redman joins Compensation and Nominating/Governance Committees; Enright chairs Audit Committee.

## SEC filing metadata
- accession: 0001140361-22-002104
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2022-01-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/0001140361-22-002104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/brhc10032872_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-002104
- JSON: https://secwatch.observer/filing/0001140361-22-002104.json
- Plain text: https://secwatch.observer/filing/0001140361-22-002104.txt

## Key facts
- Executive change
  Erin S. Enright was appointed as Director at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/0001140361-22-002104-index.htm
- Executive change
  Heather B. Redman was appointed as Director at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/0001140361-22-002104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.